ProPhase Labs, Inc. (PRPH)
Nasdaq · Healthcare · Diagnostics & Research
$0.010.00%as of Nov 5, 2026, 4:50 AM ET
- Market cap
- $156K
- Forward P/E
- 0.0
- 52-week range
- $0.0058 – $3.20
- 52-week change
- −99.67%
- EPS (trailing)
- −$0.87
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $4.3M (−35.82%)
- Net income
- −$14.7M
- Operating margin
- −415.4%
- Diluted EPS
- −$1.74
- Free cash flow
- −$8.3M
From the company’s annual report on SEC EDGAR.
About ProPhase Labs, Inc.
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA).
Headquarters: Uniondale, United States · 19 employees · prophaselabs.com